PATH, in collaboration with the Epidemiology & Disease Control Division, Government of Nepal, and B.P. Koirala Institute of Health Sciences, Dharan, is implementing a focused pharmacovigilance program for kala-azar, or visceral leishmaniasis (VL), in Nepal. The program aims to strengthen patient safety and care associated with the use of VL drugs. The results of the pharmacovigilance activities are summarized in this newsletter.